Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation

Louis S Matza,1 Glenn A Phillips,2 Dennis A Revicki,1 Haya Ascher-Svanum,3 Karen G Malley,4 Andrew C Palsgrove,1 Douglas E Faries,3 Virginia Stauffer,3 Bruce J Kinon,3 A George Awad,5 Richard SE Keefe,6 Dieter Naber71Outcomes Research, United BioSource Corporation, Bethesda, MD, 2Formerly with Eli L...

Full description

Bibliographic Details
Main Authors:	Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, Awad AG, Keefe RS, Naber D
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-07-01
Series:	Patient Preference and Adherence
Online Access:	http://www.dovepress.com/validation-of-a-patient-interview-for-assessing-reasons-for-antipsycho-a10396

Similar Items

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial
by: Faries Douglas, et al.
Published: (2012-09-01)

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy
by: Peng X, et al.
Published: (2011-04-01)

Predictors of switching antipsychotic medications in the treatment of schizophrenia
by: Stauffer Virginia L, et al.
Published: (2010-09-01)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
by: Nyhuis Allen W, et al.
Published: (2009-09-01)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
by: Correll Christoph, et al.
Published: (2005-05-01)

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
by: Zhao Zhongyun, et al.
Published: (2005-01-01)

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
by: Xiaomei Peng, et al.
Published: (2011-01-01)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
by: Correll Christoph U, et al.
Published: (2008-04-01)

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia
by: Faries Douglas E, et al.
Published: (2010-01-01)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians
by: Chen J, et al.
Published: (2011-11-01)

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial
by: Chen Lei, et al.
Published: (2011-12-01)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
by: Osuntokun Olawale, et al.
Published: (2011-05-01)

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example
by: Nyhuis Allen W, et al.
Published: (2009-05-01)

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
by: Ye W, et al.
Published: (2012-01-01)

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
by: Haynes Virginia S, et al.
Published: (2012-12-01)

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration
by: Zhao Yingnan, et al.
Published: (2009-12-01)

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study
by: Ascher-Svanum Haya, et al.
Published: (2011-08-01)

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia
by: Furiak Nicolas M, et al.
Published: (2009-01-01)

Discontinuation of antipsychotic medication in pregnancy: a cohort study.
by: Petersen, I, et al.
Published: (2014)

The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia.
by: Spineli, L, et al.
Published: (2013)

The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia
by: Spineli, L, et al.
Published: (2013)

Does slow and steady win the race? Rates of antipsychotic discontinuation, antipsychotic dose, and risk of psychotic relapse
by: McCutcheon, RA, et al.
Published: (2023)

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
by: Smolen Lee J, et al.
Published: (2009-04-01)

Dose Reduction/Discontinuation of Antipsychotic Drugs in Psychosis; Effect on Cognition and Functional Outcomes
by: Yoshie Omachi, et al.
Published: (2018-09-01)

The cost of relapse and the predictors of relapse in the treatment of schizophrenia
by: Slade Eric P, et al.
Published: (2010-01-01)

High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders
by: Anna Maria Auxilia, et al.
Published: (2023-01-01)

Letter to the Editor
by: Naber KG
Published: (2011-11-01)

Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia
by: Naber KG
Published: (2013-04-01)

Efficacy and safety of the phytotherapeutic drug Canephron&reg; N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia
by: Naber KG
Published: (2013-02-01)

Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data
by: Caballero Joshua PharmD, BCPP, FCCP, et al.
Published: (2023-08-01)

Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review
by: Andrew Thompson, et al.
Published: (2018-07-01)

An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders
by: Nadia E. Crellin, et al.
Published: (2022-03-01)

Correlates of late-onset antipsychotic treatment resistance
by: D. Fonseca De Freitas, et al.
Published: (2022-06-01)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
by: Correll CU, et al.
Published: (2019-08-01)

Clinical correlates of early onset antipsychotic treatment resistance
by: Fonseca de Freitas, D, et al.
Published: (2022)

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties
by: Montgomery W, et al.
Published: (2012-02-01)

Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis
by: J. Bogers, et al.
Published: (2021-04-01)

Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
by: Taro Kishi, et al.
Published: (2021-09-01)

Changes in Physician Antipsychotic Prescribing Preferences, 2002–2007
by: Donohue, Julie, et al.
Published: (2015)

Atypical antipsychotics, more than just an antipsychotic
by: Hiram Tendilla-Beltran, et al.
Published: (2020-01-01)